Name | 2-[2-[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3H-benzimidazol-5-yl]phenyl]propan-2-ol |
---|---|
Synonyms | Mavatrep |
Description | Mavatrep is an orally bioavailable TRPV1 antagonist (Ki=6.5 nM), exhibits minimal effect on the enzymatic activity (IC50 > 25 μM) of CYP isoforms 3A4, 1A2, and 2D6.IC50 value: 6.5 nM (Ki, for TRPV1)Target: TRPV1in vitro: Mavatrep exhibits superior pharmacodynamic properties. In a TRPV1 functional assay, using cells expressing recombinant human TRPV1 channels, Mavatrep antagonizes capsaicin-induced Ca2+ influx, with an IC50 value of 4.6 nM. Mavatrep blocks the activation of hTRPV1 channels by Capsaicin (1 μM) and by pH (5.0) in a concentration-dependent fashion, with IC50 values of 23 and 6.8 nM, respectively. in vivo: Mavatrep exhibits superior pharmacodynamic properties in the CFA model of inflammatory pain. |
---|---|
Related Catalog | |
References |
Molecular Formula | C25H21F3N2O |
---|---|
Molecular Weight | 422.44200 |
Exact Mass | 422.16100 |
PSA | 48.91000 |
LogP | 6.64650 |
Storage condition | 2-8℃ |